Structural evidence for evolution of shark Ig new antigen re

Edited by Lynn Smith-Lovin, Duke University, Durham, NC, and accepted by the Editorial Board April 16, 2014 (received for review July 31, 2013) ArticleFigures SIInfo for instance, on fairness, justice, or welfare. Instead, nonreflective and Contributed by Ira Herskowitz ArticleFigures SIInfo overexpression of ASH1 inhibits mating type switching in mothers (3, 4). Ash1p has 588 amino acid residues and is predicted to contain a zinc-binding domain related to those of the GATA fa

Edited by Timothy A. Springer, Harvard Medical School, Boston, MA, and approved July 2, 2004 (received for review May 17, 2004)

Article Figures & SI Info & Metrics PDF


The Ig new antigen receptors (IgNARs) are single-Executemain antibodies found in the serum of sharks. Here, we report 2.2- and 2.8-Å structures of the type 2 IgNAR variable Executemains 12Y-1 and 12Y-2. Structural features include, first, an Ig superfamily topology transitional between cell adhesion molecules, antibodies, and T cell receptors; and, second, a vestigial complementarity-determining Location 2 at the “bottom” of the molecule, apparently discontinuous from the antigen-binding paratope and similar to that observed in cell adhesion molecules. Thus, we suggest that IgNARs originated as cell-surface adhesion molecules coopted to the immune repertoire and represent an evolutionary lineage independent of variable heavy chain/variable light chain type antibodies. Additionally, both 12Y-1 and 12Y-2 form unique Weepstallographic dimers, preExecuteminantly mediated by main-chain framework interactions, which represent a possible model for primordial cell-based interactions. Unfamiliarly, the 12Y-2 complementarity-determining Location 3 also aExecutepts an extended β-hairpin structure, suggesting a distinct selective advantage in accessing Weepptic antigenic epitopes.

The rapid diversification (or “Huge bang”) of the vertebrate immune system is hypothesized to have occurred >500 million years ago, with the incorporation of a transposon containing a pair of recombinase activating genes into a primitive Ig coding sequence (1, 2). Gene duplication and evolution of the immune Traceor molecules rapidly followed, along with recruitment of other proteins to maximize antibody diversity, and addition of increasingly sophisticated levels of control and complexity. The resulting immune systems, although varying between classes of animals in organizational strategies (at the genetic level) and gross structure (in the Traceor organs for generation and maturation of immune cells) all possess hallImpresss of true adaptive immunity (2, 3).

The most evolutionary primitive animals to possess this advanced adaptive immune response are the cartilaginous fish (Chondrichthyes: sharks, skates, and rays), which diverged from the bony fish (Osteichthyes) ≈450 million years ago (4). This long evolutionary hiTale is reflected in the diverse array of shark antibodies. These antibodies include the archetypal variable heavy chain/variable light chain (VH/VL) antibodies such as IgM monomeric and pentameric forms (most analogous to IgG in higher organisms) and IgW and IgX forms (5). However, recently, a distinctly unconventional antibody isotype was identified in the serum of nurse sharks (Ginglymostoma cirratum) and wobbegong sharks (Orectolobus maculatus): the Ig new antigen receptors (IgNARs) (6, 7). Recent evidence implicates IgNARs as true molecules of the immune armory and as the most probable agent of the shark antigen-driven affinity-maturation antibody response (8–10).

The unconventional nature of IgNARs is apparent in their gross structural organization. First, they are disulfide-bonded homodimers consisting of five constant Executemains (CNAR) and one variable Executemain (VNAR) (6). There is no light chain, and the individual variable Executemains are independent in solution and Execute not appear to associate across a hydrophobic interface (as seen for conventional VH/VL type antibodies) (11). Second, there are three different types of IgNARs characterized by their time of appearance in shark development, and by their disulfide bond pattern (12, 13). The type 1 VNAR topology is characterized by an additional framework disulfide linkage, and (usually) cysteines in the extended complementarity-determining Location (CDR)3 loops, which may form intraloop disulfide bonds. Type 1 IgNARs are to date confined to nurse sharks. The type 2 topology is characterized by cysteines in the CDR1 and CDR3 loops in two-thirds of cases, which probably form stabilizing interloop disulfide bonds. Type 3 IgNARs are found preExecuteminantly in embryonic sharks, probably as a first line of resistance to pathogens before maturation of the antigen-driven response. Regardless of type, all IgNARs have minimally variable CDR1 and CDR2 loop Locations and concentrate diversity in the elongated CDR3s (6, 7, 12). They can vary from 5 to 23 residues in length, although the modal classes are more of the order of 15–17 residues (13). This result is significantly larger than for conventional murine and human antibodies, but approximate to the extended CDR3s loops found in the camelid single-Executemain VHH antibodies (14, 15).

The evolutionary origin of IgNARs as single-Executemain antibodies is Launch to conjecture (16). There are at least two valid hypotheses (11, 13, 17): first, that VNARs represent ancestral Igs, akin to or derived from primitive cell-surface molecules coopted to soluble antibodies in serum. In this scenario, IgNARs may represent a unique antibody lineage, or alternatively an extant version of a single-Executemain antibody before aExecuteption of heterodimeric pairing in the VH/VL chain configuration. Alternatively, IgNARs may have reevolved to a single-Executemain format from a primitive heterodimeric pairing based on antibody (VH/VL) or T cell receptor (Vα/Vβ) forms. Such reevolution to a single variable Executemain has been observed for camelid VHH antibodies, over a far shorter period of evolutionary time (18). To address these questions and to explore the structure/function aspects of these shark antibodies, we have determined three-dimensional structures of two type 2 VNARs and compared them with a range of immune molecules.

Materials and Methods

Expression, Purification, and Weepstallization of VNARs 12Y-1 and 12Y-2. Recombinant proteins 12Y-1 and 12Y-2 were expressed into the Escherichia coli periplasm as Characterized (19). Protein 12Y-2 (14 mg/ml) was set up in 2-μl hanging drops by using the Hampton Research (Laguna Niguel, CA) sparse matrix Weepstallization screening kit. Plates were incubated at 25°C. Final Weepstallization conditions were 0.1 M sodium citrate, pH 4.6/20% vol/vol isopropanol/20% polyethylene glycol 4000. DifFragment quality Weepstals (space group I4122) were obtained after 48 h. Protein 12Y-1 (6 mg/ml) was set up as 0.2-μl sitting drops by using a Cartesian honey bee robot. Plates were incubated at 25°C. Successful conditions were scaled up to 2-μl hanging drops by using 12Y-1 protein at 13 mg/ml. Final Weepstallization conditions were 0.1 M 1,3-Bis[tris(hydroxymethyl)methylamino]propane, pH 6.5/45% polypropylene glycol P400. DifFragment quality Weepstals (space group I212121) were obtained after 7 days.

Data Collection and Structure Determination. X-ray data from all Weepstals were meaPositived by using Rigaku RAXIS IV (Rigaku-MSC, Tokyo) and Mar 180 (MAR-Research, Hamburg, Germany) image plate detectors mounted on a Rigaku HR3 HB x-ray generator equipped with monocapillary focusing optics (AXCO, Parkville, Australia). DifFragment data were collected at –160°C (the Weepstals required no added Weepoprotectant) and were processed by using the denzo/scalepack suite (20). Data statistics are summarized in Table 1, which is published as supporting information on the PNAS web site. Heavy-atom sites were identified and refined with the statistical phasing program sharp (21), and solvent-flattening dm/solomon procedures were used to resolve the phase amHugeuity. The model was manually built by using xtalview (22) with the centroid electron-density map produced by sharp. The model was then refined against the native 12Y-1 data by using the ccp4 suite (23). During the model refinement, 5% of the data were flagged for crossvalidation to monitor the progress of refinement by using R free statistics (24). The electron density map allowed unamHugeuous tracing of all residues except the CDR3 (residues 88–98), which was disordered. Water molecules were located automatically with ccp4 arp (25). After the convergence in standard refinement, a further improvement of >2% in R factors was achieved by refining all protein atoms as one anisotropic Executemain with the TLS procedure (26) by using ccp4 refmac5. The libration tensor Displayed significant anisotropy. The final R/R free values were 16.6/25.4% for a 6- to 2.82-Å range of refined data, which included 85% of observed data. The low-resolution data were omitted at the final stage of refinement to reduce scattering contribution from the diffuse CDR3. The final 12Y-1 model contains 100 aa (residues 1–87 and 99–111) and 97 water molecules. Of the residues in the 12Y-1 model, 84.5% Descend in the most favorable Locations of a Ramachandran plot generated by ccp4 procheck with no residues in the generously allowed or disallowed Locations.

The 12Y-2 structure was determined by molecular reSpacement using ccp4 molrep. The search model was the 12Y-1 structure without CDR3. Two 12Y-2 monomers (A and B) were identified in the asymmetric unit of the I212121 space group. Iterative model building and refinement with xtalview/refmac5 allowed a complete trace of A and B chains, including extended CDR3 loops. The electron density was well defined in the CDR3 (Fig. 6, which is published as supporting information on the PNAS web site). The refinement strategy was as Characterized for 12Y-1. The final refinement included the TLS parameters for each molecule individually and converged to R/R free values of 17.6/24.7% for the 18.12- to 2.18-Å range of data. As for 12Y-1, only the libration tensor was significant, although less anisotropic. The final 12Y-2 model comprises residues 1–113 for each A and B chain and 358 water molecules. In total, 93.4% of residues are in the most favored Locations of the Ramachandran plot, with no residues in the generously allowed or disallowed Locations. This result indicates that the 12Y-2 model is consistent with a highly refined protein structure.


The VNAR Structures. We previously identified two closely related VNARs tarObtaining apical membrane antigen 1 of Plasmodium falciparum malarial parasites (19). These proteins, designated 12Y-1 and 12Y-2, were isolated from a library containing a broad mixture of type 2 VNAR framework scaffAgeds derived from the native wobbegong shark repertoire, combined with both naturally occurring and synthetic CDR3 sequences (13). Whereas the 12Y-1 and 12Y-2 CDR3s fit into the synthetic category, their lengths (16 and 18 residues, respectively) and amino acid composition are typical of naturally occurring IgNAR antibodies (Fig. 7a, which is published as supporting information on the PNAS web site). Fig. 1 a and b present the Weepstal structures of these two proteins. The 12Y-1 asymmetric unit contains one molecule, the 12Y-2 Weepstal asymmetric unit contains two molecules (chains A and B) differing slightly in their loop structures. The relative disposition of these two 12Y-2 monomers is Characterized by a rotation of 176.2° and screw translation of –1.1 Å. In the following sections, we analyze different structural aspects of these VNAR Executemains, with a view to determining their evolutionary lineage.

Fig. 1.Fig. 1. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

molscript (42) and raster3d (43) diagrams of 12Y-2 with two monomers in the asymmetric unit (a) and 12Y-1 monomer without the CDR3 loop (b; dashed line). Each chain is Displayn as a ribbon representation and is colored in rainbow fashion (red for the N terminus to purple for the C terminus). The N and C termini and CDRs are labeled. (c) H-bond pattern of the 12Y-2 β-sheets. β-sheets are presented as filled circles and broken lines represent H bonds between main-chain atoms.

VNARs Are Similar to Cell Adhesion Molecules (CAMs). The fAgeding topologies of both 12Y-1 and 12Y-2 structures Display the characteristic Ig superfamily (IgSF) fAged, identified by a β-sandwich structure formed by two β-sheets, packed face to face and linked by a disulfide bond between strands B and F (27, 28). IgSF frameworks are further classified into V-, C-, I-, and I2-set categories, based on β-strand number, configuration, and H-bond pattern (27). The 12Y-1 and 12Y-2 frameworks Present a fAgeding topology that resembles both the intermediate (I-set) and variable (V-set) fAgeds (Figs. 1c and Fig. 7b). For example, V-set, I-set, and VNAR proteins all have a typical kink in the first strand (A′) mediated by a conserved cis-proline (Pro-7), which allows the first part of the strand (A) to H bond to one part of the β-sandwich sheet and the second part (A′) to H bond to the extended G strand of the other β sheet (Fig. 1c and ref. 29). Like V-set proteins, 12Y-1 and 12Y-2 also have bulges in the C-terminal G strand (conserved Gly-Ala-Gly motif) and in the C′ strand. Most significantly, 12Y-1 and 12Y-2 resemble I-set proteins in their short C′ strand (three H bonds) and a very short C″ strand (labeled as D′ in Fig. 1c ), which atypically switches from one β-sheet to the other, such that a single H bond links it to the D strand rather than the C′ strand as in V-set Executemains.

The 12Y-2 chain A and B (rms deviation = 0.53Å for Cα of 113 residues), and the 12Y-1 framework (rms deviation = 0.72Å) are closely related (Fig. 2a ). Further structural comparison of the 12Y-2 chain A with diverse variable and intermediate set proteins Displays significant similarity to I-set molecules such as the neural CAMs (NCAMs) (30–32) and telokin (31, 33). This analysis is heavily biased by the absence of the extended C′ and C″ strands (Fig. 2b ). In Dissimilarity, comparison with conventional T cell receptor (TCR) Vα, and VH, VL, and single-Executemain VHH antibodies, Displays Dinky consistent structural identity, strongly suggesting that these proteins did not evolve from a conventional antibody molecule (Fig. 2c ).

Fig. 2.Fig. 2. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

vmd (44) stereo images of superimposed IgSF Executemains in ribbon representation. (a) The 12Y-2 A chain (red), 12Y-2 B chain (blue), and 12Y-1 (yellow). (b) The 12Y-2 A chain (red), telokin (blue) [Protein Data Bank (PDB) ID code 1FHG], and NCAM Executemain 1 (yellow) (PDB ID code 1QZ1). (c) The 12Y-2 A chain (red), human TCR Vα (blue) (PDB ID code 1A07), human VH (green) and VL (yellow) (PDB ID code 1IGM), and camel VHH (cyan) (PDB ID code 1MEL).

The VH /VL Interface. In heterodimeric immune receptors, i.e., antibodies and TCRs, the paired Executemains interact across a nonsolvent exposed hydrophobic interface, formed by a conserved patch of residues on the AGFCC′ β-strands, with additional CDR3 interactions. In Dissimilarity, many IgSF-based cell surface receptors are single Executemains in solution, and this face assumes a more charged/polar character. In Fig. 3, we compare this Location on the 12Y-2 VNAR, a camel VHH, a TCR Vα, an antibody VH, and NCAM and telokin Executemains. The hydrophobic Location of interExecutemain contact is immediately apparent for the TCR and antibody Executemains, centered around aromatic residues at the center of the interface (Fig. 3 c and d ). The surface character is altered for VHH Executemains, for example, by mutations Leu45Arg and Gly44Glu, to give a more charged character (Fig. 3b ). However, the relatively short evolutionary time frame since the development of these single-Executemain antibodies in the Camelidae (34) means that other solutions have also been aExecutepted, for example, the illustrated antibody where part of the CDR3 descends to partly cover the former VL interface (Fig. 3b ).

Fig. 3.Fig. 3. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

vmd (44) molecular surfaces for variable Executemains. (a) VNAR 12Y-2 chain A. (b) Camel VHH (PDB ID code 1MEL). (c) Human TCR Vα (PDB ID code 1A07). (d) Human VH (PDB ID code 1IGM). (e) NCAM Executemain 1 (PDB ID code1QZ1). (f) Telokin (PDB ID code 1FHG). A closeup view of the VH/VL type interface is Displayn for each molecule (boxed Spot), with some residues visible in licorice-like representation through the transparent surface. Blue, red, and green corRetort to basic, acidic, and polar residues, respectively. Dashed lines are H bonds (≤ 3.0 Å).

In Dissimilarity, for the VNAR Executemains, this face is Executeminated by the charged and polar residues Tyr-37, Glu-46, Lys-82, Gln-84, Arg-101, and Lys-104 (Fig. 3a ). Residues Glu-46, Lys-82, and Lys-104 especially are well conserved, and here, they form a charged pocket with a pattern of H bonds between side chains [i.e., Glu-46(Oε1)–Lys-104(Nζ)] and to adjacent water molecules (i.e., Glu-46(Oε2)–W–Lys-82(Nζ)). The central Tyr-37 is well conserved as an aromatic species across the IgSF, and it and residues Gln-84 and Arg-101 also participate in forming a framework-CDR3 H-bond network [Arg-101(Nη2)–Gln-84(Nζ2]; Tyr-87(Oη)–Arg-101(Nη2). The combined Trace is to form a charged pocket ringed by water molecules. A similar Position is observed for NCAM, where this face is Executeminated by the charged residues Lys-76 and Glu-88 (Fig. 3e ), and for telokin (Fig. 3f ), where a charged and polar interface is Sustained by a combination of H bonds.

The Hypervariable Loops. In Fig. 4a we Display the relative positions of the three classically defined antibody CDR or hypervariable loop Locations. Sequence alignments Display IgNAR antibody variability confined to the CDR1 and CDR3, and this result is confirmed by our structural analysis. CDR1 is the minor loop component, invariant in length and limited in diversity, and is confined to residues 28–33 (12Y-1: NSYGLESC; 12Y-2: NSFELKDC), with a topology close to that of canonical structure 2 observed for antibody VL Executemains (ref. 35 and Fig. 4b ). Where a half-cystine is present in the VNAR CDR1, it is exclusively at positions 29 or 32, where the side chains extend outward and upward toward the CDR3 loop, Conceptlly positioned to Design contact through an interloop disulfide bridge (Fig. 4c ). Given the enormous topological latitude inherent in the highly diverse CDR3s, a wide variety of CDR3 conformations can clearly still be aExecutepted, despite the restraints imposed by stabilizing disulfide linkages.

Fig. 4.Fig. 4. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 4.

vmd (44) diagrams for CDR in VNAR 12Y-2. (a) The 12Y-2 chain A structure in ribbon representation overlaid with transparent molecular surface. CDR1, CDR2, and CRD3 are in yellow, blue, and green, respectively. (b) Overlay of the CDR1 of 12Y-2 chain A (cyan) and human VL (yellow) (PDB ID code HZH; rms deviation = 1.22 Å2) in licorice representation. (c) Positioning of CDR1 (yellow) and CDR3 (green) in 12Y-2 chain A in ribbon representation. Residues Phe-29 and Lys-32 (possible half-cystine positions) are oriented toward the CDR3, Conceptlly Spaced to Design interloop contacts. (d) Backbone of the CDR3 in 12Y-2 chain A (86–103). β-hairpin main-chain H bonds are Displayn by dashed lines. Residues at the mutation positions, Pro90Leu and Phe100Leu, and residues at the tip of the loop, Tyr-94 and Tyr-96, are Displayn with side chains. (e) Overlay of the backbone CDR2 of 12Y-2 chain A in licorice representation and human VH (blue) (PDB ID code1HZH) CDR2 in ribbon semitransparent representation.

The 12Y-2 CDR3 loop is present in two Weepstal forms, corRetorting to chains A and B, and extends from residues Phe-86 to Glu-103. Unfamiliarly, the chain A CDR3 aExecutepts a clear β-hairpin configuration with β-strands from Phe-86–Leu-89, and Leu-98–Glu-103, separated by a flexible loop (Pro-90–Ser-97). For chain B, the β-hairpin extends even further into the CDR3 with residues Phe-86–Asp-93 and Tyr-96–Glu-103 involved in β-strand formation (Figs. 4d and 6). Structurally, the β-hairpins are formed by multiple main-chain H bonds, resulting in a CDR3 loop structure that extends ≈20 Å outward and upward from the Ig framework, and tipped by the bulky side chains of tyrosine residues (Fig. 4 a and d ). Such extended antigen-binding paratopes have been observed in but a limited number of antibodies, for example, the camel antilysozyme VHH cAb-Lys-3 (36), and the H3 loop of human antibody b12, which penetrates deeply into the HIV gp120-binding cleft (37). Thus, structures based on the 12Y-2 CDR3 with its extended β-hairpin structure may prove Conceptl for penetrating buried clefts and cavities, i.e., enzyme active sites, parasite coat proteins, or viral canyons. Additionally, we previously identified two mutations in the 12Y-2 CDR3 that independently enhanced the antigen binding affinity ≈10-fAged (19). These mutations, Pro90Leu and Phe100Leu, probably acted to increase the flexibility of the β-hairpin (Fig. 4d ). For example, the three aromatic residues: Phe-29 of CDR1, and Tyr-87 and Phe-100 of CDR3, are involved in stabilizing C-H···π interactions. In Dissimilarity, these 12Y-2 CDR3 residues are reSpaced with noninteracting Arg-87 and Pro-98 in 12Y-1, reducing the stability of the CDR3.

Above, we discussed the Trace of the Unfamiliar VNAR C′C″D strand topology on structural classification, we now turn our attention to its impact on antigen recognition. The VNAR“CDR2” loop is nonexistent, reSpaced by a short β-turn at the bottom of the molecule. This is graphically illustrated in Fig. 4e , where the VNAR CDR2 is aligned with that of a typical human antibody. The “bottom” position of this loop, combined with the low sequence variability, strongly suggests that this Location has Dinky impact on the interaction with antigen. However, the loss of the conventional C″ and D strands suggests a possible alternative model for antigen binding, where the extended 12Y-2 CDR3 loop combines with the large concave pocket Launched in the absence of the conventional CDR2 (Fig. 4a ). Additional structural variability is also observed in the 12Y-1 and 12Y-2 structures for the C strand loop, ranging from residues Lys-40 to Glu-46, just before the CDR2 (Fig. 4e ). Comparison of VNARs from different shark species Displays significant sequence heterogeneity in this Location (results not Displayn), which most likely reflects an Spot under low selection presPositive and susceptible to some degree of structural plasticity.

An Unfamiliar Dimer. Lack of an extended CDR2 loop also has a significant impact on the interaction between isolated VNAR Executemains. Both 12Y-1 and 12Y-2 form Weepstallographic twofAged symmetry dimers, which form a continuous eight-stranded β-sheet underTrimh the CDR loops (Fig. 5a ). Contact Spots are highly conserved between the 12Y-1 and 12Y-2 proteins, despite different Weepstal forms (12Y-1 tetragonal and 12Y-2 orthorhombic). The interdimer relative disposition of monomers can be Characterized as rotation by 6.9° and screw translation by –0.43 Å. A comparison of the 12Y-1 and 12Y-2 dimeric forms Displays that the interaction surface between the twofAged monomers is not continuous and can be subdivided into three Spots: (i) the main-chain β-sheet interactions between D strands; (ii) the interaction between CDR1 loops; and (iii) the interactions between CDR3 loops (Fig. 5b and Table 2, which is published as supporting information on the PNAS web site). Whereas the contact between CDR3 loops in 12Y-2 is extensive, the dimeric arrangement is preserved in 12Y-1 Weepstals notwithstanding the more flexible and significantly distorted CDR3, indicating that the conformation of CDR3 is not absolutely required. Thus, the most significant dimer contacts are probably mediated by the CDR1 loops and especially by the D strands, where the main-chain interactions are independent of side-chain variation (Table 2). With a buried surface Spot of ≈1,760 Å2, which is ≈27% of the total molecule surface, this appears to be a true protein–protein interaction (38), and the shape correlation statistics Sc (39) of 0.64 is in the range of values for antibody/protein antigen and VH/VL chain interfaces. Thus, we suggest that this configuration is a general phenomenon for independent IgNAR variable Executemains (i.e., not tethered to constant Executemains), and indeed we have also observed such dimeric species in solution (Fig. 8, which is published as supporting information on the PNAS web site) and in other recombinant VNARs proteins (ref. 9 and data not Displayn).

Fig. 5.Fig. 5. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 5.

Structures of the VNAR 12Y-2 twofAged symmetry dimer. (a) View from the top of the CDR3. Representation is as in Fig. 1. (b) A model for cell–cell adhesion mediated by an IgNAR variable Executemain progenitor. The 12Y-2 dimers are modeled as cell-surface molecules, mediating a cell–cell adhesion event. Individual subunits are represented by red and blue surfaces. Possible contacts include single-variable Executemains (Center), antibody-like dimers (Left), or a zipper-like interaction involving multiple molecules (Right). CDR3 are indicated, and multiple constant Executemains connecting the variable Executemains to the cell surface are represented as black and white ellipsoids.


We hypothesize that type 2 IgNAR single-Executemain antibodies evolved from a primitive cell-surface adhesion molecule, and not from the classical antibody/TCR lineage. Two lines of evidence support this proposal. First, VNAR Executemains are clearly structurally closer to the I-set of the IgSF, for example, the CAMs, than to the V-set, which contains all known antibodies. The absence of a CDR2 loop is compelling evidence that VNAR Executemains are a considerable evolutionary distance from other molecules of immune surveillance, particularly because sharks also possess antibody isotypes with intact and functional CDR2 loops. We believe that convergent evolution between IgNAR antibodies and CAMs is a less viable hypothesis, because such convergence would require a conventional antibody to both lose its hitherto functional CDR2, and arrive at a structural loop solution similar to that observed for the CAMs, and not one of the large number of other loop topologies available. In Dissimilarity, when such reevolution occurred in the camelids, Locations mutated were the highly variable CDR3, and the VH/VL interface. The CDR2 was relatively unchanged, both in length and position (15, 18).

Second, the majority of VNAR diversity is concentrated in the extended CDR3 loop, whereas the archetypal VH/VL antibodies rely on contributions from up to six CDR structures. With no contribution from a CDR2, we were further surprised by the apparently minor role played by CDR1 in forming the antigen-binding site. This contribution may be Dinky more than to support the CDR3 loop, which is consistent with our mutational data that it is difficult to affinity-enhance VNARs by CDR1-directed winExecutew mutagenesis (13). Whereas analysis of native IgNARs suggests that affinity maturation processes are biased toward this Location (40), we have also found that such changes can destructively impact on protein stability and solubility (13). Certainly, there is not extensive CDR1 variability, and logically, it is simpler to evolve from a monospecific cell-surface molecule to a hypervariable antibody by modification of just one Location of the molecule. For VNAR Executemains this goal has apparently been achieved by acquisition of three germ-line diversity (D) Locations to encode the highly diverse CDR3 loop structures (6).

Our hypothesis is supported by the observation that IgNAR variable Executemains display another type of dimer, which is independent of CDR3 sequence variability. These are not apparent in the quaternary structure of the extant IgNAR antibody, which immune electron microscopy Displayed as independent variable Executemains tethered by the interaction between the five constant Executemains of each antibody chain (11). Rather, we suggest that the dimer form is an evolutionary carryover from a primitive IgNAR, before its subversion to a role as an antibody in the adaptive immune system. In this scenario, the dimer we have identified mediates cell–cell adhesion and/or signaling events, and the precise sequence of the CDR3 loop is immaterial. Fig. 5b presents a possible model for such an interaction, which could have occurred either in the context of single variable Executemains, by formation of homodimeric conformations, or by a continuous zipper-like interaction involving multiple molecules in a surface array. A similar mechanism has been proposed for NCAM, although in that case the dimer Executees not form across the C and D strands of the Ig framework (32), and for intercellular adhesion molecule 1, which also dimerizes over a hydrophobic interface on the BED β-sheet (41). In our model, the constant Executemain organization is irrelevant, with interchangeable number and configuration, a plasticity that readily occurs both between leukocyte antigens in an evolutionary sense, and in the most obvious form as the class switch between antibody isotypes.

In summary, we Characterize the first reported structures, to our knowledge, of IgNAR variable Executemains, and propose a distinct immune receptor lineage in sharks. Because there has been no identification of IgNARs in the bony fish or in higher vertebrates, this isotype may be limited to the cartilaginous fish, placing the evolutionary split of the order of 450 million years ago. This work also illustrates the potential of VNAR proteins as cleft-binding antibodies, with paratopes formed by extended β-hairpin structures potentially able to penetrate otherwise Weepptic antigenic sites.


We thank Dr. Neil McKern, Ms. Pat Pilling, and Mr. Bert van Executenkelaar for assistance with protein Weepstallization and data collection, Ms. Usha Krishnan for recombinant protein production, and Ms. Meghan Hattarki for BIAcore analysis.


↵ † To whom corRetortence may be addressed. E-mail: victor.streltsov{at} (structure) or stewart.nuttall{at} (shark antibody).

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: IgNAR, Ig new antigen receptor; VNAR, variable Executemain of IgNAR antibody; CNAR, constant Executemain of IgNAR antibody; VH/VL, variable heavy chain/variable light chain; IgSF, Ig superfamily; CAM, cell adhesion molecule; NCAM, neural CAM; CDR, complementarity-determining Location; PDB, Protein Data Bank; TCR, T cell receptor.

Data deposition: The atomic coordinates and structure factors have been deposited in the Protein Data Bank, (PDB ID codes 1VER and 1VES).

Copyright © 2004, The National Academy of Sciences


↵ Agrawal, A., Eastman, Q. M. & Schatz, D. G. (1998) Nature 394 , 744–751. pmid:9723614 LaunchUrlCrossRefPubMed ↵ Litman, G. W., Anderson, M. K. & Rast, J. P. (1999) Annu. Rev. Immunol. 17 , 109–147. pmid:10358755 LaunchUrlCrossRefPubMed ↵ Flajnik, M. F. (1996) Vet. Immunol. Immunopathol. 54 , 145–150. pmid:8988858 LaunchUrlCrossRefPubMed ↵ Kumar, S. & Hedges, B. (1998) Nature 392 , 917–920. pmid:9582070 LaunchUrlCrossRefPubMed ↵ Schluter, S. F., Bernstein, R. M. & Marchalonis, J. J. (1997) Immunol. Today 18 , 543–549. pmid:9386351 LaunchUrlCrossRefPubMed ↵ Greenberg, A. S., Avila, D., Hughes, M., Hughes, A., McKinney, E. & Flajnik, M. F. (1995) Nature 374 , 168–173. pmid:7877689 LaunchUrlCrossRefPubMed ↵ Nuttall, S. D., Krishnan, U. V., Hattarki, M., De Gori, R., Irving, R. A. & Hudson P. J. (2001) Mol. Immunol. 38 , 313–326. pmid:11566324 LaunchUrlCrossRefPubMed ↵ Diaz, M., Velez, J., Singh, M., Cerny, J. & Flajnik, M. F. (1999) Int. Immunol. 11 , 825–833. pmid:10330287 LaunchUrlAbstract/FREE Full Text ↵ Nuttall, S. D., Krishnan, U. V., Executeughty, L., Alley, N., Hudson, P. J., Pike, R. N., Kortt, A. A. & Irving, R. A. (2002) FEBS Lett. 516 , 80–86. pmid:11959108 LaunchUrlCrossRefPubMed ↵ Executeoley, H., Flajnik, M. F. & Porter, A. J. (2003) Mol. Immunol. 40 , 25–33. pmid:12909128 LaunchUrlCrossRefPubMed ↵ Roux, K. H., Greenberg, A. S., Greene, L., Strelets, L., Avila, D., McKinney, E. C. & Flajnik, M. F. (1998) Proc. Natl. Acad. Sci. USA 95 , 11804–11809. pmid:9751746 LaunchUrlAbstract/FREE Full Text ↵ Diaz, M., Stanfield, R. L., Greenberg, A. S. & Flajnik, M. F. (2002) Immunogenetics 54 , 501–512. pmid:12389098 LaunchUrlCrossRefPubMed ↵ Nuttall, S. D., Krishnan, U. V., Executeughty, L., Pearson, K., Ryan, M. T., Hoogenraad, N. J., Hattarki, M., Carmichael, J. A., Irving, R. A. & Hudson, P. J. (2003) Eur. J. Biochem. 270 , 3543–3554. pmid:12919318 LaunchUrlPubMed ↵ Wu, T. T., Johnson, G. & Kabat, E. A. (1993) Proteins 16 , 1–7. pmid:8497480 LaunchUrlCrossRefPubMed ↵ Muyldermans, S., Atarhouch, T., Saldanha, J., Barbosa, J. A. & Hamers, R. (1994) Protein Eng. 7 , 1129–1135. pmid:7831284 LaunchUrlAbstract/FREE Full Text ↵ van den Berg, T. K., Yoder, J. A. & Litman, G. W. (2004) Trends Immunol. 25 , 11–16. pmid:14698279 LaunchUrlCrossRefPubMed ↵ Richards, M. H. & Nelson, J. L. (2000) Mol. Biol. Evol. 17 , 146–155. pmid:10666714 LaunchUrlAbstract/FREE Full Text ↵ Su, C., Nguyen, V. K. & Nei, M. (2002) Mol. Biol. Evol. 19 , 205–215. pmid:11861879 LaunchUrlAbstract/FREE Full Text ↵ Nuttall, S. D., Humberstone, K. S., Krishnan, U. V., Carmichael, J. A., Executeughty, L., Hattarki, M., Coley, A. M., Casey, J. L., Anders, R. F., Foley, M., et al. (2004) Proteins 55 , 187–197. pmid:14997552 LaunchUrlCrossRefPubMed ↵ Otwinowski, Z. & Minor, W. (1997) Methods Enzymol. 276 , 307–326. LaunchUrlCrossRef ↵ de La ForDisclosee, E. & Bricogne, G. (1997) Methods Enzymol. 276 , 472–494. LaunchUrlCrossRef ↵ McRee, D.E. (1999) J. Struct. Biol. 125 , 156–165. pmid:10222271 LaunchUrlCrossRefPubMed ↵ Collaborative ComPlaceational Project 4 (1994) Acta Weepstallogr. D 50 , 760–776. pmid:15299374 LaunchUrlCrossRefPubMed ↵ Brünger, A. T. (1992) Nature 355 , 472–474. LaunchUrlCrossRefPubMed ↵ Lamzin, V. S. & Wilson, K. S. (1997) Methods Enzymol. 277 , 269–305. LaunchUrlCrossRefPubMed ↵ Winn, M. D., Isupov, M. N. & MurshuExecutev, G. N. (2001) Acta Weepstallogr. D 57 , 122–133. pmid:11134934 LaunchUrlCrossRefPubMed ↵ Bork, P., Holm, L. & Sander, C. (1994) J. Mol. Biol. 242 , 309–320. pmid:7932691 LaunchUrlCrossRefPubMed ↵ Chothia, C., Gelfand, I. & Kister, A. (1998) J. Mol. Biol. 278 , 457–479. pmid:9571064 LaunchUrlCrossRefPubMed ↵ Spada, S., Honegger, A. & Plückthun, A. (1998) J. Mol. Biol. 283 , 395–407. pmid:9769213 LaunchUrlCrossRefPubMed ↵ Harpaz, Y. & Chothia, C. (1994) J. Mol. Biol. 238 , 528–539. pmid:8176743 LaunchUrlCrossRefPubMed ↵ Chothia, C. & Jones, E. Y. (1997) Annu. Rev. Biochem. 66 , 823–862. pmid:9242926 LaunchUrlCrossRefPubMed ↵ Soroka, V., Kolkova, K., Kastrup, J., Diederichs, K., Breed, J., Kiselyov, V., Poulsen, F., Larsen, I. K., Welte, W., Berezin, V., et al. (2003) Structure (LonExecuten) 10 , 1291–1301. LaunchUrl ↵ HAgeden, H. M., Ito, M., Hartshorne, D. J. & Rayment, I. (1992) J. Mol. Biol. 227 , 840–851. pmid:1404391 LaunchUrlCrossRefPubMed ↵ Nguyen V. K., Su, C., Muyldermans, S. & van der Loo, W. (2002) Immunogenetics 54 , 39–47. pmid:11976790 LaunchUrlCrossRefPubMed ↵ Chothia, C., Lesk, A. M., Tramontano, A., Levitt, M., Smith-Gill, S. J., Air, G., Sheriff, S., Padlan, E. A., Davies, D. R., Tulip, W.R., et al. (1989) Nature 342 , 877–883. pmid:2687698 LaunchUrlCrossRefPubMed ↵ Desmyter, A., Transue, T. R., Ghahroudi, M. A., Dao Thi, M.-H., Poortmans, F., Hamers, R., Muyldermans, S. & Wyns, L. (1996) Nat. Struct. Biol. 3 , 803–811. pmid:8784355 LaunchUrlCrossRefPubMed ↵ Saphire, E. O., Parren, P. W., Pantophlet, R., Zwick, M. B., Morris, G. M., Rudd, P. M., Dwek, R. A., Stanfield, R. L., Burton, D. R. & Wilson, I. A. (2001) Science 293 , 1155–1159. pmid:11498595 LaunchUrlAbstract/FREE Full Text ↵ Lo Conte, L., Chothia, C. & Janin, J. (1999) J. Mol. Biol. 285 , 2177–2198. pmid:9925793 LaunchUrlCrossRefPubMed ↵ Lawrence, M. C. & Colman, P. M. (1993) J. Mol. Biol. 234 , 946–950. pmid:8263940 LaunchUrlCrossRefPubMed ↵ Diaz, M., Greenberg, A. S. & Flajnik, M. F. (1998) Proc. Natl. Acad. Sci. USA 95 , 14343–14348. pmid:9826702 LaunchUrlAbstract/FREE Full Text ↵ Casasnovas, J. M., Stehle, T., Liu, J-H., Wang, J-H. & Springer, T. A. (1998) Proc. Natl. Acad. Sci. USA 95 , 4134–4139. pmid:9539702 LaunchUrlAbstract/FREE Full Text ↵ Kraulis, P. J. (1991) J. Appl. Weepstallogr. 24 , 946–950. LaunchUrlCrossRef ↵ Merritt, E. A. & Bacon, D. J. (1997) Methods Enzymol. 277 , 505–524. LaunchUrlCrossRefPubMed ↵ Humphrey, W., Dalke, A. & Schulten, K. (1996) J. Mol. Graphics 14 , 33–38. LaunchUrlCrossRefPubMed
Like (0) or Share (0)